AbbVie price target raised to $195 from $165 at Berenberg
Berenberg raised the firm’s price target on AbbVie (ABBV) to $195 from $165 and keeps a Hold rating on the shares. The firm increased estimates ...
Mehmet Oz, Trump’s nominee to run Medicare and Medicaid, will testify before a Senate committee Friday
Trump’s allegiance to Oz was further emphasized on Tuesday when the president announced he was nominating Oz’s son-in-law, ...
Guggenheim Reaffirms Their Buy Rating on Pfizer (PFE)
Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...
DelveInsight Business Research, LLP: Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
DelveInsight Business Research, LLP: ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...